Improving access to novel agents for childhood leukemia
Cet article passe en revue les stratégies et les initiatives pour faciliter la mise en oeuvre d'essais cliniques de nouveaux traitements des leucémies pédiatriques
Leukemia is the most common pediatric cancer. Despite great progress in the development of curative therapy, leukemia remains a leading cause of death from disease in childhood, and survivors are at life-long risk of complications of treatment. New agents are needed to further increase cure rates and decrease treatment-associated toxicities. The complex biology and aggressive nature of childhood leukemia, coupled with the relatively small patient population available for study, pose specific challenges to the development of new therapies. In this review, the authors discuss strategies and initiatives designed to improve access to new agents in the treatment of pediatric leukemia. Cancer 2015. © 2015 American Cancer Society.
Cancer , résumé, 2014